Clinical trials sponsored by Innovent Biologics (Suzhou) Co. Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by Innovent Biologics (Suzhou) Co. Ltd.

• A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
  NCT07066098 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
  NCT07399067 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
  NCT07255209 · Phase: Phase 3 · Ages: 12 Years to 18 Years · Sex: All (male and female) · 1 location
• A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
  NCT06931028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
  NCT06862908 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of IBI363 in Subjects With Advanced Melanoma
  NCT06081920 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of IBI363 in Subjects with Advanced Solid Malignancies
  NCT06281678 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
  NCT07330934 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
  NCT06797297 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
  NCT05504278 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
  NCT07469800 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
  NCT07483554 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
  NCT07122687 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
  NCT07008287 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Preliminary Activity of BI115 in Advanced SCLC
  NCT07559019 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
  NCT06613009 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations

Common questions

How many trials is Innovent Biologics (Suzhou) Co. Ltd. recruiting for?

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 16 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.